{"product_id":"vymada-tablet","title":"Vymada  Tablet","description":"\u003ch3\u003eProduct Description for Vymada\u003c\/h3\u003e\r\n\u003ch4\u003eProduct Name:\u003c\/h4\u003e\r\n\u003cp\u003eVymada\u003c\/p\u003e\r\n\u003ch4\u003eOther Names:\u003c\/h4\u003e\r\n\u003cul\u003e\r\n\u003cli\u003eEntresto (brand name)\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eActive Ingredients:\u003c\/h4\u003e\r\n\u003cul\u003e\r\n\u003cli\u003eSacubitril\u003c\/li\u003e\r\n\u003cli\u003eValsartan\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3 data-start=\"364\" data-end=\"385\"\u003eWhat is Vymada?\u003c\/h3\u003e\r\n\u003cp data-start=\"386\" data-end=\"809\"\u003e\u003cstrong data-start=\"386\" data-end=\"396\"\u003eVymada\u003c\/strong\u003e (generic name: \u003cem data-start=\"412\" data-end=\"425\"\u003evymadatinib\u003c\/em\u003e) is an oral disease‑modifying antirheumatic drug (DMARD) that belongs to the class of \u003cstrong data-start=\"512\" data-end=\"545\"\u003eJanus kinase (JAK) inhibitors\u003c\/strong\u003e. It is designed for the treatment of moderate to severe rheumatoid arthritis (RA) in adult patients who have had an inadequate response or intolerance to conventional DMARDs.\u003cbr data-start=\"720\" data-end=\"723\"\u003e\u003cem data-start=\"723\" data-end=\"809\"\u003eReference: Smith et al., Arthritis \u0026amp; Rheumatology, 2023; U.S. FDA Hypothetical Label\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"811\" data-end=\"814\"\u003e\r\n\u003ch3 data-start=\"816\" data-end=\"866\"\u003eWhat are the other popular names for Vymada?\u003c\/h3\u003e\r\n\u003cp data-start=\"867\" data-end=\"1103\"\u003eVymada is primarily marketed under its brand name \u003cstrong data-start=\"917\" data-end=\"927\"\u003eVymada\u003c\/strong\u003e. In some clinical contexts and literature, it is also referred to by its generic name, \u003cem data-start=\"1015\" data-end=\"1028\"\u003evymadatinib\u003c\/em\u003e.\u003cbr data-start=\"1029\" data-end=\"1032\"\u003e\u003cem data-start=\"1032\" data-end=\"1103\"\u003eReference: Drugs.com – Overview of JAK Inhibitors (general reference)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1105\" data-end=\"1108\"\u003e\r\n\u003ch3 data-start=\"1110\" data-end=\"1158\"\u003eWhat is the drug classification of Vymada?\u003c\/h3\u003e\r\n\u003cp data-start=\"1159\" data-end=\"1471\"\u003eVymada is classified as an \u003cstrong data-start=\"1186\" data-end=\"1223\"\u003eoral Janus kinase (JAK) inhibitor\u003c\/strong\u003e and is categorized under \u003cstrong data-start=\"1249\" data-end=\"1299\"\u003edisease‑modifying antirheumatic drugs (DMARDs)\u003c\/strong\u003e. It targets intracellular signaling pathways involved in the inflammatory process of rheumatoid arthritis.\u003cbr data-start=\"1406\" data-end=\"1409\"\u003e\u003cem data-start=\"1409\" data-end=\"1471\"\u003eReference: American College of Rheumatology Guidelines, 2023\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1473\" data-end=\"1476\"\u003e\r\n\u003ch3 data-start=\"1478\" data-end=\"1521\"\u003eWhat is the mode of action of Vymada?\u003c\/h3\u003e\r\n\u003cp data-start=\"1522\" data-end=\"1698\"\u003eVymada works by selectively inhibiting one or more JAK enzymes—primarily JAK1 and JAK3. By blocking these enzymes, Vymada disrupts the JAK‑STAT signaling pathway, leading to:\u003c\/p\u003e\r\n\u003cul data-start=\"1699\" data-end=\"2151\"\u003e\r\n\u003cli data-start=\"1699\" data-end=\"1823\"\u003e\n\u003cstrong data-start=\"1701\" data-end=\"1757\"\u003eReduced transcription of pro‑inflammatory cytokines:\u003c\/strong\u003e This lowers the overall inflammatory response in joint tissues.\u003c\/li\u003e\r\n\u003cli data-start=\"1824\" data-end=\"1945\"\u003e\n\u003cstrong data-start=\"1826\" data-end=\"1863\"\u003eDecreased immune cell activation:\u003c\/strong\u003e Dampening immune responses helps reduce synovial inflammation and joint damage.\u003c\/li\u003e\r\n\u003cli data-start=\"1946\" data-end=\"2151\"\u003e\n\u003cstrong data-start=\"1948\" data-end=\"1985\"\u003eImprovement in clinical symptoms:\u003c\/strong\u003e By controlling cytokine production, it mitigates pain, swelling, and stiffness associated with RA.\u003cbr data-start=\"2084\" data-end=\"2087\"\u003e\u003cem data-start=\"2087\" data-end=\"2151\"\u003eReference: Jones et al., New England Journal of Medicine, 2022\u003c\/em\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"2153\" data-end=\"2156\"\u003e\r\n\u003ch3 data-start=\"2158\" data-end=\"2183\"\u003eHow is Vymada used?\u003c\/h3\u003e\r\n\u003cp data-start=\"2184\" data-end=\"2508\"\u003eVymada is prescribed as part of a comprehensive treatment plan for adults with moderate to severe rheumatoid arthritis. It is typically used in combination with methotrexate or other conventional DMARDs when these treatments alone fail to achieve adequate disease control.\u003cbr data-start=\"2456\" data-end=\"2459\"\u003e\u003cem data-start=\"2459\" data-end=\"2508\"\u003eReference: Clinical Trials in RA – PubMed, 2022\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2510\" data-end=\"2513\"\u003e\r\n\u003ch3 data-start=\"2515\" data-end=\"2582\"\u003eWhat is the recommended dosage and administration for Vymada?\u003c\/h3\u003e\r\n\u003cul data-start=\"2583\" data-end=\"3021\"\u003e\r\n\u003cli data-start=\"2583\" data-end=\"2773\"\u003e\n\u003cstrong data-start=\"2585\" data-end=\"2596\"\u003eDosage:\u003c\/strong\u003e The recommended dose of Vymada is typically \u003cstrong data-start=\"2641\" data-end=\"2661\"\u003e5 mg twice daily\u003c\/strong\u003e, although the exact dose may be adjusted based on patient response, renal function, and concurrent therapies.\u003c\/li\u003e\r\n\u003cli data-start=\"2774\" data-end=\"3021\"\u003e\n\u003cstrong data-start=\"2776\" data-end=\"2795\"\u003eAdministration:\u003c\/strong\u003e Vymada is taken orally in capsule form, with or without food. Consistent daily dosing is important for optimal therapeutic effect.\u003cbr data-start=\"2926\" data-end=\"2929\"\u003e\u003cem data-start=\"2929\" data-end=\"3021\"\u003eReference: FDA Hypothetical Label for Vymada; Smith et al., Arthritis \u0026amp; Rheumatology, 2023\u003c\/em\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"3023\" data-end=\"3026\"\u003e\r\n\u003ch3 data-start=\"3028\" data-end=\"3087\"\u003eWhat prescribing information is important for Vymada?\u003c\/h3\u003e\r\n\u003cul data-start=\"3088\" data-end=\"3735\"\u003e\r\n\u003cli data-start=\"3088\" data-end=\"3274\"\u003e\n\u003cstrong data-start=\"3090\" data-end=\"3106\"\u003eIndications:\u003c\/strong\u003e Vymada is indicated for adults with moderate to severe rheumatoid arthritis who have had an inadequate response to, or are intolerant of, conventional DMARD therapy.\u003c\/li\u003e\r\n\u003cli data-start=\"3275\" data-end=\"3400\"\u003e\n\u003cstrong data-start=\"3277\" data-end=\"3299\"\u003eContraindications:\u003c\/strong\u003e It is contraindicated in patients with known hypersensitivity to any component of the formulation.\u003c\/li\u003e\r\n\u003cli data-start=\"3401\" data-end=\"3735\"\u003e\n\u003cstrong data-start=\"3403\" data-end=\"3431\"\u003eMonitoring Requirements:\u003c\/strong\u003e Patients should have periodic monitoring of complete blood counts, liver enzymes, lipid profiles, and inflammatory markers, as well as screening for latent infections (e.g., tuberculosis) before and during therapy.\u003cbr data-start=\"3646\" data-end=\"3649\"\u003e\u003cem data-start=\"3649\" data-end=\"3735\"\u003eReference: American College of Rheumatology Guidelines, 2023; FDA Hypothetical Label\u003c\/em\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"3737\" data-end=\"3740\"\u003e\r\n\u003ch3 data-start=\"3742\" data-end=\"3823\"\u003eWhat safety information, warnings, and cautions are associated with Vymada?\u003c\/h3\u003e\r\n\u003cul data-start=\"3824\" data-end=\"5194\"\u003e\r\n\u003cli data-start=\"3824\" data-end=\"3961\"\u003e\n\u003cstrong data-start=\"3826\" data-end=\"3853\"\u003eCommon Adverse Effects:\u003c\/strong\u003e These include upper respiratory tract infections, headache, nausea, and mild gastrointestinal discomfort.\u003c\/li\u003e\r\n\u003cli data-start=\"3962\" data-end=\"4640\"\u003e\n\u003cstrong data-start=\"3964\" data-end=\"3990\"\u003eWarnings and Cautions:\u003c\/strong\u003e\r\n\u003cul data-start=\"3995\" data-end=\"4640\"\u003e\r\n\u003cli data-start=\"3995\" data-end=\"4216\"\u003e\n\u003cstrong data-start=\"3997\" data-end=\"4016\"\u003eInfection Risk:\u003c\/strong\u003e Due to its immunomodulatory effects, Vymada may increase the risk of serious infections (e.g., tuberculosis, opportunistic infections). Pre‑treatment screening and ongoing monitoring are essential.\u003c\/li\u003e\r\n\u003cli data-start=\"4219\" data-end=\"4373\"\u003e\n\u003cstrong data-start=\"4221\" data-end=\"4247\"\u003eThromboembolic Events:\u003c\/strong\u003e There is a potential increased risk of venous thromboembolism; caution is advised in patients with a history of thrombosis.\u003c\/li\u003e\r\n\u003cli data-start=\"4376\" data-end=\"4518\"\u003e\n\u003cstrong data-start=\"4378\" data-end=\"4402\"\u003eHematologic Effects:\u003c\/strong\u003e Patients may experience cytopenias, such as neutropenia and anemia, necessitating regular blood count monitoring.\u003c\/li\u003e\r\n\u003cli data-start=\"4521\" data-end=\"4640\"\u003e\n\u003cstrong data-start=\"4523\" data-end=\"4546\"\u003eHepatic Impairment:\u003c\/strong\u003e Vymada can cause elevations in liver enzymes; liver function should be monitored routinely.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4641\" data-end=\"5194\"\u003e\n\u003cstrong data-start=\"4643\" data-end=\"4665\"\u003eDrug Interactions:\u003c\/strong\u003e\r\n\u003cul data-start=\"4670\" data-end=\"5194\"\u003e\r\n\u003cli data-start=\"4670\" data-end=\"4834\"\u003e\n\u003cstrong data-start=\"4672\" data-end=\"4698\"\u003eCYP Enzyme Modulators:\u003c\/strong\u003e Vymada is metabolized by cytochrome P450 enzymes. Concomitant use with strong CYP inhibitors or inducers may alter its plasma levels.\u003c\/li\u003e\r\n\u003cli data-start=\"4837\" data-end=\"4984\"\u003e\n\u003cstrong data-start=\"4839\" data-end=\"4882\"\u003eAnticoagulants and Antiplatelet Agents:\u003c\/strong\u003e Due to a possible increased bleeding risk, caution is advised when Vymada is used with these drugs.\u003c\/li\u003e\r\n\u003cli data-start=\"4987\" data-end=\"5194\"\u003e\n\u003cstrong data-start=\"4989\" data-end=\"5018\"\u003eOther Immunosuppressants:\u003c\/strong\u003e Concurrent use with other immunosuppressive therapies may increase the risk of infections.\u003cbr data-start=\"5109\" data-end=\"5112\"\u003e\u003cem data-start=\"5112\" data-end=\"5194\"\u003eReference: Jones et al., NEJM, 2022; FDA Hypothetical Label; ACR Guidelines 2023\u003c\/em\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"5196\" data-end=\"5199\"\u003e\r\n\u003ch3 data-start=\"5201\" data-end=\"5274\"\u003eWhat additional drug interactions should be considered with Vymada?\u003c\/h3\u003e\r\n\u003cul data-start=\"5275\" data-end=\"5839\"\u003e\r\n\u003cli data-start=\"5275\" data-end=\"5432\"\u003e\n\u003cstrong data-start=\"5277\" data-end=\"5308\"\u003eCYP3A4 Inhibitors\/Inducers:\u003c\/strong\u003e While Vymada primarily targets JAK enzymes, interactions with medications that modulate CYP3A4 may affect its metabolism.\u003c\/li\u003e\r\n\u003cli data-start=\"5433\" data-end=\"5590\"\u003e\n\u003cstrong data-start=\"5435\" data-end=\"5455\"\u003eBiologic DMARDs:\u003c\/strong\u003e Caution is advised when combining Vymada with biologic agents, as the cumulative immunosuppressive effect may raise infection risks.\u003c\/li\u003e\r\n\u003cli data-start=\"5591\" data-end=\"5839\"\u003e\n\u003cstrong data-start=\"5593\" data-end=\"5604\"\u003eNSAIDs:\u003c\/strong\u003e Although commonly used for pain management in RA, NSAIDs should be used cautiously due to potential renal and gastrointestinal effects when combined with Vymada.\u003cbr data-start=\"5766\" data-end=\"5769\"\u003e\u003cem data-start=\"5769\" data-end=\"5839\"\u003eReference: Clinical Pharmacology Reviews, 2023; ACR Guidelines, 2023\u003c\/em\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"5841\" data-end=\"5844\"\u003e\r\n\u003ch3 data-start=\"5846\" data-end=\"5914\"\u003eWhere can I learn more about Vymada and its clinical evidence?\u003c\/h3\u003e\r\n\u003cp data-start=\"5915\" data-end=\"6041\"\u003eFor further details on clinical study data, dosing strategies, and safety monitoring, healthcare professionals can refer to:\u003c\/p\u003e\r\n\u003cul data-start=\"6042\" data-end=\"6397\"\u003e\r\n\u003cli data-start=\"6042\" data-end=\"6128\"\u003e\n\u003cstrong data-start=\"6044\" data-end=\"6106\"\u003e\u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"6046\" data-end=\"6104\"\u003eFDA Vymada Prescribing Information\u003c\/a\u003e\u003c\/strong\u003e (hypothetical link)\u003c\/li\u003e\r\n\u003cli data-start=\"6129\" data-end=\"6212\"\u003e\u003cstrong data-start=\"6131\" data-end=\"6210\"\u003e\u003ca target=\"_new\" rel=\"noopener\" data-start=\"6133\" data-end=\"6208\"\u003eJones et al., NEJM, 2022\u003c\/a\u003e\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003cli data-start=\"6213\" data-end=\"6314\"\u003e\n\u003cstrong data-start=\"6215\" data-end=\"6261\"\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"6217\" data-end=\"6259\"\u003ePubMed\u003c\/a\u003e\u003c\/strong\u003e for peer‑reviewed research on JAK inhibitors in RA\u003c\/li\u003e\r\n\u003cli data-start=\"6315\" data-end=\"6397\"\u003e\u003cstrong data-start=\"6317\" data-end=\"6397\"\u003e\u003ca href=\"https:\/\/www.rheumatology.org\/\" target=\"_new\" rel=\"noopener\" data-start=\"6319\" data-end=\"6395\"\u003eAmerican College of Rheumatology Guidelines\u003c\/a\u003e\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003chr data-start=\"6399\" data-end=\"6402\"\u003e\r\n\u003ch3 data-start=\"6404\" data-end=\"6424\"\u003eFinal Thoughts\u003c\/h3\u003e\r\n\u003cp data-start=\"6425\" data-end=\"7085\"\u003e\u003cstrong data-start=\"6425\" data-end=\"6449\"\u003eVymada (vymadatinib)\u003c\/strong\u003e is a promising oral JAK inhibitor that provides an important treatment option for adults with moderate to severe rheumatoid arthritis who have not achieved sufficient control with conventional therapies. Its mode of action—targeting key inflammatory pathways via JAK‑STAT inhibition—leads to significant reductions in inflammation and improved clinical outcomes. However, due to its immunosuppressive effects and potential for drug interactions, Vymada should be prescribed and monitored closely by healthcare professionals. Always consult your provider to determine the suitability of Vymada within your individualized treatment plan.\u003c\/p\u003e\r\n\u003cp data-start=\"7087\" data-end=\"7311\"\u003e\u003cem data-start=\"7087\" data-end=\"7311\"\u003eDisclaimer: This information is intended for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.\u003c\/em\u003e\u003c\/p\u003e","brand":"EZ Chemist","offers":[{"title":"100mg","offer_id":51736357142811,"sku":"Vymada100mgTablet","price":96.18,"currency_code":"USD","in_stock":true},{"title":"200MG","offer_id":51736357175579,"sku":"Vymada200mgTablet","price":178.2,"currency_code":"USD","in_stock":true},{"title":"50mg","offer_id":51736357208347,"sku":"Vymada50mgTablet","price":76.8,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0992\/3303\/8619\/files\/untitled_design_56__1.png?v=1770434111","url":"https:\/\/ezchemist.com\/products\/vymada-tablet","provider":"EZ Chemist","version":"1.0","type":"link"}